Benzinga's Top #PreMarket Losers

shares fell 12.52% to $14.26 in pre-market trading. Infinity Pharmaceuticals' Phase 2 study Of Duvelisib with background methotrexate in patients with moderate-to-severe rheumatoid arthritis did not meet primary endpoint.

shares dropped 7.93% to $41.00 in pre-market trading after the company lowered its FY2014 sales guidance.

fell 6.44% to $66.48 in pre-market trading after the company issued an update on Epidilex. Sativex didn't meet primary endpoint in first trial.

shares dropped 4.57% to $51.53 in pre-market trading after the company announced the pricing of a three million share offering.

shares declined 4.22% to $180.00 in pre-market trading after the company provided update on Phase 2 clinical trial with Eculizumab.